232 related articles for article (PubMed ID: 33024552)
1. Green tea influence on iron overload in thalassemia intermedia patients: a randomized controlled trial.
Al-Momen H; Hussein HK; Al-Attar Z; Hussein MJ
F1000Res; 2020; 9():1136. PubMed ID: 33024552
[No Abstract] [Full Text] [Related]
2. Deferasirox for managing iron overload in people with thalassaemia.
Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
5. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
[TBL] [Abstract][Full Text] [Related]
6. Deferasirox for managing iron overload in people with thalassaemia.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
[TBL] [Abstract][Full Text] [Related]
7. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.
Inati A; Kahale M; Sbeiti N; Cappellini MD; Taher AT; Koussa S; Nasr TA; Musallam KM; Abbas HA; Porter JB
Pediatr Blood Cancer; 2017 Jan; 64(1):188-196. PubMed ID: 27576370
[TBL] [Abstract][Full Text] [Related]
8. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
Ladis V; Berdousi H; Gotsis E; Kattamis A
Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
[TBL] [Abstract][Full Text] [Related]
9. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
[TBL] [Abstract][Full Text] [Related]
10. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.
Taher AT; Porter J; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Galanello R; Karakas Z; Lawniczek T; Ros J; Zhang Y; Habr D; Cappellini MD
Blood; 2012 Aug; 120(5):970-7. PubMed ID: 22589472
[TBL] [Abstract][Full Text] [Related]
11. Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia.
Voskaridou E; Plata E; Douskou M; Sioni A; Mpoutou E; Christoulas D; Dimopoulou M; Terpos E
Ann Hematol; 2011 Jan; 90(1):11-5. PubMed ID: 20661572
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study.
DivakarJose RR; Delhikumar CG; Ram Kumar G
Indian J Pediatr; 2021 Apr; 88(4):330-335. PubMed ID: 32661609
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial.
Premawardhena A; Perera C; Wijethilaka MN; Wanasinghe SK; Rajakaruna RHMG; Samarasinghe RANKK; Williams S; Mettananda S
BMJ Open; 2024 Feb; 14(2):e077342. PubMed ID: 38331857
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
Taher A; El-Beshlawy A; Elalfy MS; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Hmissi A; Al Jefri A
Eur J Haematol; 2009 Jun; 82(6):458-65. PubMed ID: 19187278
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.
Pennell DJ; Porter JB; Cappellini MD; El-Beshlawy A; Chan LL; Aydinok Y; Elalfy MS; Sutcharitchan P; Li CK; Ibrahim H; Viprakasit V; Kattamis A; Smith G; Habr D; Domokos G; Roubert B; Taher A
Blood; 2010 Mar; 115(12):2364-71. PubMed ID: 19996412
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
Cappellini MD; Bejaoui M; Agaoglu L; Porter J; Coates T; Jeng M; Lai ME; Mangiagli A; Strauss G; Girot R; Watman N; Ferster A; Loggetto S; Abish S; Cario H; Zoumbos N; Vichinsky E; Opitz H; Ressayre-Djaffer C; Abetz L; Rofail D; Baladi JF
Clin Ther; 2007 May; 29(5):909-917. PubMed ID: 17697909
[TBL] [Abstract][Full Text] [Related]
17. Using of deferasirox and deferoxamine in refractory iron overload thalassemia.
Takpradit C; Viprakasit V; Narkbunnam N; Vathana N; Phuakpet K; Pongtanakul B; Sanpakit K; Buaboonnam J
Pediatr Int; 2021 Apr; 63(4):404-409. PubMed ID: 32856363
[TBL] [Abstract][Full Text] [Related]
18. Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.
Gomber S; Jain P; Sharma S; Narang M
Indian Pediatr; 2016 Mar; 53(3):207-10. PubMed ID: 27029681
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.
Pathare A; Taher A; Daar S
Ann Hematol; 2010 Apr; 89(4):405-9. PubMed ID: 19798501
[TBL] [Abstract][Full Text] [Related]
20. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
Cappellini MD; Bejaoui M; Agaoglu L; Canatan D; Capra M; Cohen A; Drelichman G; Economou M; Fattoum S; Kattamis A; Kilinc Y; Perrotta S; Piga A; Porter JB; Griffel L; Dong V; Clark J; Aydinok Y
Blood; 2011 Jul; 118(4):884-93. PubMed ID: 21628399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]